Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 5

Looking Ahead and Key Takeaways

November 20, 2024

Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.

EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM

Now Viewing

EP. 5: Looking Ahead and Key Takeaways

EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7

EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Please comment on the most significant advancements on the horizon for frontline therapy in both transplant-ineligible patients with newly diagnosed multiple myeloma.
Provide your key takeaways from the latest clinical trial data and how you anticipate these findings will impact your day-to-day clinical practice.